Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jan 19, 2021 1:36pm
105 Views
Post# 32327520

RE:New investors from the deal

RE:New investors from the deal

IF that is a fact and I think this is a big IF they could have announced in one PR  a Private Placement for 10 million Units and a Public Offering for the remainder of the Units....The dilutive effect would have been the same but the optics and the perception would have been a lot different


SPCEO1 wrote: I have heard that three institutions accounted for 60% of the shares sold in the deal. That would give these three 10.8% or so of the company, Hopefully, they are long term holders and not in it just for the warrants. If these three have the same stakes, we may never learn who they are since I don't think they are required to report if they own below 5%.

I have an idea for the company to consider. It would seem fait to me if the company granted outright to all current shareholders the same warrant they just sold to the new investors. TH will need more money to complete the phase III NASH trial and the cash that would likely be derived from those warrants being exercised might take care of what they need three years from now. Better yet, make our warrants expire in two years.    

 

<< Previous
Bullboard Posts
Next >>